GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Great Novel Therapeutics Biotech & Medicals (ROCO:7427) » Definitions » Return-on-Tangible-Asset

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Return-on-Tangible-Asset : -9.96% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Great Novel Therapeutics Biotech & Medicals Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Great Novel Therapeutics Biotech & Medicals's annualized Net Income for the quarter that ended in Dec. 2023 was NT$-54.98 Mil. Great Novel Therapeutics Biotech & Medicals's average total tangible assets for the quarter that ended in Dec. 2023 was NT$552.26 Mil. Therefore, Great Novel Therapeutics Biotech & Medicals's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 was -9.96%.

The historical rank and industry rank for Great Novel Therapeutics Biotech & Medicals's Return-on-Tangible-Asset or its related term are showing as below:

ROCO:7427' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -53.9   Med: -41.46   Max: -13.4
Current: -13.4

During the past 6 years, Great Novel Therapeutics Biotech & Medicals's highest Return-on-Tangible-Asset was -13.40%. The lowest was -53.90%. And the median was -41.46%.

ROCO:7427's Return-on-Tangible-Asset is ranked better than
71.96% of 1548 companies
in the Biotechnology industry
Industry Median: -40.065 vs ROCO:7427: -13.40

Great Novel Therapeutics Biotech & Medicals Return-on-Tangible-Asset Historical Data

The historical data trend for Great Novel Therapeutics Biotech & Medicals's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Great Novel Therapeutics Biotech & Medicals Return-on-Tangible-Asset Chart

Great Novel Therapeutics Biotech & Medicals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial -52.69 -50.17 -32.75 -26.89 -15.28

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only -23.66 -44.77 -27.97 -16.10 -9.96

Competitive Comparison of Great Novel Therapeutics Biotech & Medicals's Return-on-Tangible-Asset

For the Biotechnology subindustry, Great Novel Therapeutics Biotech & Medicals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Great Novel Therapeutics Biotech & Medicals's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Great Novel Therapeutics Biotech & Medicals's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Great Novel Therapeutics Biotech & Medicals's Return-on-Tangible-Asset falls into.



Great Novel Therapeutics Biotech & Medicals Return-on-Tangible-Asset Calculation

Great Novel Therapeutics Biotech & Medicals's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-61.54/( (273.435+532.095)/ 2 )
=-61.54/402.765
=-15.28 %

Great Novel Therapeutics Biotech & Medicals's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=-54.984/( (572.422+532.095)/ 2 )
=-54.984/552.2585
=-9.96 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Dec. 2023) net income data.


Great Novel Therapeutics Biotech & Medicals  (ROCO:7427) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Great Novel Therapeutics Biotech & Medicals Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Great Novel Therapeutics Biotech & Medicals's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Business Description

Traded in Other Exchanges
N/A
Address
No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Headlines

No Headlines